arithmos— AI-powered custom index builder. You’re viewing a shared index.
Index
GLP-1 Obesity Boom Index
official“An index of pharma companies, manufacturers, and adjacent winners from the GLP-1 obesity-drug megatrend — Ozempic, Wegovy, Mounjaro, and the next generation of incretin therapies.” — by Olamide Al-Sayed
built · 2026-04-30 21:38·rebalance · quarterly·next run · 2026-07-30
backtest · S&P 500 (SPX)·range
CAGR—
Annual vol—
Sharpe—
Sortino—
Max drawdown—
Best year—
Worst year—
risk-free raterf = 4.50%
vs S&P 500 (SPX) · 1M—
vs S&P 500 (SPX) · 1Y—
vs S&P 500 (SPX) · 2Y—
vs S&P 500 (SPX) · 3Y—
vs S&P 500 (SPX) · 5Y—
vs S&P 500 (SPX) · 10Y—
no backtest data
sharpe ratio
| ticker | weight | YTD | 1Y | 3Y | 5Y | 10Y |
|---|---|---|---|---|---|---|
| LLY | 25.0% | — | — | — | — | — |
| NVO | 22.0% | — | — | — | — | — |
| VKTX | 12.0% | — | — | — | — | — |
| AMGN | 10.0% | — | — | — | — | — |
| ZBH | 8.0% | — | — | — | — | — |
| WW | 8.0% | — | — | — | — | — |
| HIMS | 8.0% | — | — | — | — | — |
| WBA | 7.0% | — | — | — | — | — |
| weighted | 100% | — | — | — | — | — |
attribution factsheet
holdings · 8
click a row to drill in ↗NameAllocation· cap 25%Rationale
LLYEli LillyHealthcare25.00%Mounjaro/Zepbound dominance and orforglipron oral pipeline.NVONovo NordiskHealthcare22.00%Ozempic/Wegovy creator and largest insulin franchise globally.VKTXViking TherapeuticsHealthcare12.00%VK2735 dual-agonist oral and injectable obesity Phase 2.AMGNAmgenHealthcare10.00%MariTide bispecific weight-loss with monthly dosing potential.ZBHZimmer BiometHealthcare8.00%Joint replacements benefit as obese patients become surgical candidates.WWWW InternationalHealthcare8.00%Pivoting to GLP-1 prescribing through clinic acquisition.HIMSHims & Hers HealthHealthcare8.00%Compounded GLP-1 telehealth distribution at scale.WBAWalgreens Boots AllianceHealthcare7.00%Pharmacy distribution for the largest Rx category in pharma history.
▾
▾
▾
▾
▾
▾
▾
▾
weighting · market_cap · cap=25%
rebalance · quarterly
